BLTE
BELITE BIO, INC
NASDAQ · Healthcare · Biotechnology · US
$147.34
+3.19%Oct 14, 2026, 20:00 UTC
BELITE BIO, INC announced that it submitted marketing authorization applications for tinlarebant to regulatory authorities in Singapore, the United Kingdom and Switzerland for Stargardt disease type 1.
Source:Oct 1, 2026, 12:00 UTC
Belite Bio announced that data on its tinlarebant for Stargardt disease will be presented at the Innovate Retina conference on October 8, 2026, and at the American Academy of Ophthalmology 2026 meeting on October 9-12, 2026, both in New Orleans, Louisiana.
Source:Sep 29, 2026, 00:00 UTC
Belite Bio announced that its data will be presented at the Euretina Innovation Spotlight on September 30, 2026, and at Euretina on October 1-4, 2026, in Vienna, Austria.
Source:Sep 10, 2026, 01:45 UTC
Belite Bio CFO and Director Chuang Hao-Yuan sold 62,395 American depositary shares for approximately $12.8 million on September 4 and September 8, 2026, under a Rule 10b5-1 trading plan.
Source:Sep 8, 2026, 10:00 UTC
Belite Bio submitted a New Drug Application to Japan's Ministry of Health, Labour and Welfare under the Sakigake designation system for tinlarebant to treat Stargardt disease type 1.
Source:Aug 21, 2026, 12:00 UTC
Belite Bio announced that its data will be presented at two upcoming medical conferences in August 2026.
Source:Aug 11, 2026, 20:01 UTC
The U.S. Food and Drug Administration accepted and granted Priority Review designation to Belite Bio's New Drug Application for tinlarebant for the treatment of Stargardt Disease Type 1, with a PDUFA date set for February 12, 2027.
Aug 6, 2026, 12:00 UTC
Belite Bio announced it will host a webcast on August 13, 2026, to discuss its second quarter 2026 financial results and provide a business update.
Jun 13, 2026, 01:30 UTC
Belite Bio completed its rolling submission of a New Drug Application to the U.S. Food and Drug Administration for tinlarebant for the treatment of Stargardt disease type 1.